Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18318912 | ALDH1 ANTIGEN-PULSED DENDRITIC CELLS | Final Rejection | The Regents of the University of Michigan |
| 18025883 | A Scoring Method for an Anti-B7H4 Antibody-Drug Conjugate Therapy | Non-Final OA | Medimmune Limited |
| 17638725 | TARGETED DELIVERY OF TUMOR MATRIX MODIFYING ENZYMES | Final Rejection | The Research Foundation for The State University of New York |
| 18325912 | METHODS FOR TREATING MISMATCH REPAIR DEFICIENT LOCALLY ADVANCED RECTAL CANCER USING DOSTARLIMAB | Non-Final OA | Sloan-Kettering Institute for Cancer Research |
| 18906489 | Compositions and Methods for the Delivery of Therapeutic Biologics for Treatment of Disease | Non-Final OA | Elektrofi, Inc. |
| 18552504 | ANTI-TAU ANTIBODIES AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17995273 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING LIPID-PHOTOTHERMAL NANOPARTICLE HAVING ANTIBODY BOUND TO SURFACE | Non-Final OA | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION |
| 18316672 | EPHA3 AND MULTI-VALENT TARGETING OF TUMORS | Non-Final OA | Wake Forest University Health Sciences |
| 17997963 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HEPATITIS B VIRUS | Non-Final OA | The Wistar Institute of Anatomy and Biology |
| 18026799 | COMBINATION THERAPIES | Non-Final OA | Mirati Therapeutics, Inc. |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | Non-Final OA | Seagen Inc. |
| 18122839 | COMBINATIONS OF AN ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, A PLATINUM-BASED ANTINEOPLASTIC DRUG, AND A TAXANE | Non-Final OA | King Faisal Specialist Hospital & Research Centre |
| 18251523 | Combination Treatment of Cancer | Non-Final OA | GlaxoSmithKline Intellectual Property (NO. 4) LTD. |
| 18043497 | COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION | Non-Final OA | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE |
| 18007248 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING A CANCER | Non-Final OA | Assistance Publique-Hôpitaux de Paris |
| 18016316 | CANCER ANTIGEN FOR EARLY CANCER DETECTION | Non-Final OA | UCT RESEARCH AND DEVELOPMENT INC. |
| 17927728 | TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | Non-Final OA | PEMI31 THERAPEUTICS INC. |
| 17789746 | Composition and Use of Engineered Monoclonal Antibodies Refractory to Tumor Immuno-Suppressive Factors | Non-Final OA | Navrogen, Inc. |
| 17789327 | CANCER TREATMENT METHOD AND MEDICINE | Non-Final OA | ZERIA PHARMACEUTICAL CO., LTD. |
| 17775981 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Final Rejection | SURFACE ONCOLOGY, LLC |
| 17765153 | ANTIGEN-BINDING PROTEIN CONSTRUCTS AND USES THEREOF | Final Rejection | Mythic Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy